|
bioMérieux is a family-owned company specializing in in vitro diagnostics, providing solutions for pathogen detection and identification to healthcare professionals and industry players. The company develops and manufactures diagnostic tests and instruments for clinical microbiology, molecular diagnostics, and point-of-care testing, serving markets in Europe, the Middle East, Africa, and globally. Key product lines include the BIOFIRE and FILMARRAY platforms for respiratory and pneumonia panels, the SPINCHIP point-of-care platform for cardiac troponin measurement, and solutions for antimicrobial resistance and pharmaceutical quality control. bioMérieux supports public health initiatives, including rapid diagnostics for Ebola response and sepsis management, and operates a distribution network across multiple regions. Summarised from the company's own disclosures, fiscal year ended Mar 2026 |
Industry Diagnostics & Research | Homepage biomerieux.com |
| Sector Healthcare | IR page biomerieux.com/corp/en/investors.html | |
|
Tags
in vitro diagnostics, clinical microbiology, molecular diagnostics, point-of-care testing, antimicrobial resistance, respiratory diagnostics, sepsis diagnostics, pharmaceutical quality control, pathogen detection, public health, BIOFIRE, FILMARRAY, SPINCHIP, GO•28
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | € 11.319B |
| Market cap (USD) | $ 12.51B |
| P/E | 24.47 |
| PEG | — |
| P/BV | 2.76 |
| P/S | 2.77 |
| P/OCF | 14.36 |
| P/FCF | — |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 9.6% |
| ROI | 9.7% |
| ROIC | 9.5% |
| Profit margin | 9.8% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | No |
| Revenue up 3y | Yes |
| Revenue up 5y | Yes |
| Earnings growth 3y (net profit CAGR) | -4.2% |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | No |
| Buying back stock | No |
| Diluting (TTM) | No |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 13 |
| Quality score | 23.5% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Balance sheet detail | |||||||
| Other receivables (EUR) | 61.1M | 82.2M | 118M | 153M | 172M | 176M | 179M |
| Cash and deposits (EUR) | 275M | 389M | 804M | 553M | 352M | 450M | 570M |
| Intangible assets (EUR) | 508M | 431M | 412M | 625M | 529M | 492M | 402M |
| Right-of-use assets (EUR) | 131M | 130M | 124M | 120M | 149M | 170M | 141M |
| Cash flow detail | |||||||
| Operating cash flow (EUR) | 408M | 583M | 811M | 475M | 445M | 667M | 788M |
| Purchases of property, plant and equipment (EUR) | -273M | -278M | -290M | -287M | -338M | -346M | -335M |
| Change in receivables (cash effect) (EUR) | -400,000 | -500,000 | -2.7M | -500,000 | 500,000 | -3.7M | -4.6M |
| Change in inventories (cash effect) (EUR) | 71M | 82.9M | 62.4M | 92.1M | -193M | -85.1M | -10.1M |
| Change in payables (cash effect) (EUR) | -32.9M | -4.7M | -24.2M | -9.9M | 3.4M | -600,000 | 3.4M |
| Dividends paid (cash effect) (EUR) | -41.3M | -22.5M | -73.1M | -101M | -100M | -100M | -106M |
| Share buybacks (cash effect) (EUR) | 0.00 | -18.4M | -3.8M | -157M | -12.7M | -37.6M | -18.2M |
| Income taxes paid (cash effect) (EUR) | 81.6M | 116M | 185M | 224M | -204M | -206M | -152M |
| Share-based compensation (EUR) | 9.4M | 9.9M | 12.4M | 13M | 19.7M | 23.4M | 26.5M |
| Operating cash flow before change in receivables (EUR) | 408M | 583M | 814M | 476M | 445M | 671M | 793M |
| Free cash flow (OCF - PPE - intangibles) (EUR) | 135M | 305M | 521M | 188M | 107M | 322M | 453M |
| Income detail | |||||||
| Research and development expense (EUR) | 374M | 399M | 389M | 447M | 460M | 492M | 507M |
| ↳ 5y CAGR | +5.6% | +4.9% | |||||
| Total comprehensive income (EUR) | 287M | 251M | 761M | 585M | 183M | 574M | -5.1M |
| Comprehensive income to owners (EUR) | 289M | 254M | 760M | 597M | 219M | 581M | -3M |
| Reported | Mar 17, 2021 | Mar 17, 2021 | Mar 17, 2022 | Mar 22, 2023 | Mar 27, 2024 | Mar 21, 2025 | Mar 16, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpRegulated information filed with the AMF (info-financiere.gouv.fr), newest first, titles as filed. Voting-rights totals, own-share transactions, threshold crossings and availability notices are left out. The link opens the filed document. Press releases from the company's own website, newest first.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding Biomerieux
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| SAGP | 1.51% | 14,764 | $ 1.16M | Jun 30, 2026 |
| QLTI | 0.93% | 31,667 | $ 2.761M | Aug 31, 2026 |
| DFIS | 0.07% | 40,301 | $ 4.116M | Nov 12, 2026 |
| AVDE | 0.05% | 89,221 | $ 9.005M | Nov 16, 2026 |
| AVSD | 0.04% | 1,385 | $ 139.785K | Nov 16, 2026 |
| DFIC | 0.02% | 31,345 | $ 3.202M | Nov 12, 2026 |
| DFAX | 0.01% | 17,645 | $ 1.802M | Nov 12, 2026 |
| DFAI | 0.01% | 23,391 | $ 2.389M | Nov 12, 2026 |
| DFSI | 0.00% | 389 | $ 39.734K | Nov 12, 2026 |